Connect Other Current Liab vs Common Stock Shares Outstanding Analysis
CNTB Stock | USD 1.78 0.06 3.49% |
Connect Biopharma financial indicator trend analysis is way more than just evaluating Connect Biopharma prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Connect Biopharma is a good investment. Please check the relationship between Connect Biopharma Other Current Liab and its Common Stock Shares Outstanding accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Connect Biopharma Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.
Other Current Liab vs Common Stock Shares Outstanding
Other Current Liab vs Common Stock Shares Outstanding Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Connect Biopharma Other Current Liab account and Common Stock Shares Outstanding. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Connect Biopharma's Other Current Liab and Common Stock Shares Outstanding is -0.21. Overlapping area represents the amount of variation of Other Current Liab that can explain the historical movement of Common Stock Shares Outstanding in the same time period over historical financial statements of Connect Biopharma Holdings, assuming nothing else is changed. The correlation between historical values of Connect Biopharma's Other Current Liab and Common Stock Shares Outstanding is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Current Liab of Connect Biopharma Holdings are associated (or correlated) with its Common Stock Shares Outstanding. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Shares Outstanding has no effect on the direction of Other Current Liab i.e., Connect Biopharma's Other Current Liab and Common Stock Shares Outstanding go up and down completely randomly.
Correlation Coefficient | -0.21 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Other Current Liab
Common Stock Shares Outstanding
The total number of shares of a company's common stock that are currently owned by all its shareholders.Most indicators from Connect Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Connect Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Connect Biopharma Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. At present, Connect Biopharma's Enterprise Value Over EBITDA is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 0.27, whereas Tax Provision is forecasted to decline to about 114 K.
2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 4.1M | 6.9M | 988K | 938.6K | Total Operating Expenses | 621.5M | 785.2M | 64.8M | 61.6M |
Connect Biopharma fundamental ratios Correlations
Click cells to compare fundamentals
Connect Biopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Connect Biopharma fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Other Current Liab | 4.2M | 12.8M | 32.8M | 24.4M | 3.0M | 2.8M | |
Total Current Liabilities | 27.4M | 38.0M | 114.7M | 108.8M | 24.3M | 23.1M | |
Retained Earnings | (292.1M) | (1.1B) | (2.4B) | (3.2B) | (539.3M) | (566.3M) | |
Accounts Payable | 22.8M | 24.6M | 81.2M | 83.1M | 7.7M | 7.3M | |
Net Receivables | 1.2M | 1.7M | 47.3M | 1.6M | 178K | 169.1K | |
Other Stockholder Equity | 42.5M | 48.1M | 4.2B | (71.2M) | 648.3M | 876.5M | |
Total Current Assets | 362.8M | 1.1B | 1.8B | 1.1B | 121.0M | 114.9M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.C | Citigroup | |
CRM | Salesforce | |
MSFT | Microsoft |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Connect Biopharma Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Complementary Tools for Connect Stock analysis
When running Connect Biopharma's price analysis, check to measure Connect Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Connect Biopharma is operating at the current time. Most of Connect Biopharma's value examination focuses on studying past and present price action to predict the probability of Connect Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Connect Biopharma's price. Additionally, you may evaluate how the addition of Connect Biopharma to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance |
Is Connect Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Connect Biopharma. If investors know Connect will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Connect Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.08) | Return On Assets (0.27) | Return On Equity (0.46) |
The market value of Connect Biopharma is measured differently than its book value, which is the value of Connect that is recorded on the company's balance sheet. Investors also form their own opinion of Connect Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Connect Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Connect Biopharma's market value can be influenced by many factors that don't directly affect Connect Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Connect Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Connect Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Connect Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.